For the quarter ending 2025-09-30, LAB has $539,636K in assets. $139,977K in debts. $129,418K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 129,418 | 158,617 | ||
| Short-term investments | 65,485 | 78,468 | ||
| Accounts receivable, net | 13,536 | 14,612 | ||
| Inventory | 25,418 | 24,170 | ||
| Prepaid expenses and other current assets | 7,906 | 7,081 | ||
| Current assets held for sale | 230,676 | 223,089 | ||
| Total current assets | 472,439 | 506,037 | ||
| Property and equipment, gross | 67,438 | - | ||
| Less accumulated depreciation and amortization | 47,075 | - | ||
| Construction-in-progress | 375 | - | ||
| Property and equipment, net | 20,738 | 22,678 | ||
| Operating lease right-of-use asset, net | 23,453 | 24,568 | ||
| Other non-current assets | 3,521 | 3,682 | ||
| Long-term investments | 19,485 | - | ||
| Non-current assets held for sale | 0 | 0 | ||
| Total assets | 539,636 | 556,965 | ||
| Accounts payable | 6,619 | 7,329 | ||
| Accrued liabilities | 30,810 | 24,207 | ||
| Operating lease liabilities, current | 5,113 | 5,094 | ||
| Deferred revenue, current | 40,111 | 40,167 | ||
| Deferred grant income, current | 3,098 | 3,243 | ||
| Current liabilities held for sale | 22,214 | 17,984 | ||
| Total current liabilities | 107,965 | 98,024 | ||
| Convertible notes, non-current | 299 | 299 | ||
| Deferred tax liability | 1,139 | 1,081 | ||
| Operating lease liabilities, non-current | 21,977 | 23,223 | ||
| Deferred revenue, non-current | 2,366 | 2,786 | ||
| Deferred grant income, non-current | 5,031 | 5,767 | ||
| Other non-current liabilities | 1,200 | 1,250 | ||
| Non-current liabilities held for sale | 0 | 0 | ||
| Total liabilities | 139,977 | 132,430 | ||
| Common stock 0.001 par value, 600,000 shares authorized at september 30, 2025 and december 31, 2024 402,194 and 396,110 shares issued at september 30, 2025 and december 31, 2024, respectively 383,614 and 377,530 shares outstanding at september 30, 2025 and december 31, 2024, respectively | 401 | 400 | ||
| Additional paid-in capital | 1,726,032 | 1,717,673 | ||
| Accumulated other comprehensive loss | -477 | -1,928 | ||
| Accumulated deficit | -1,279,830 | -1,245,143 | ||
| Treasury stock at cost 18,580 shares at september 30, 2025 and december 31, 2024 | 46,467 | 46,467 | ||
| Total stockholders' equity | 399,659 | 424,535 | ||
| Total liabilities and stockholders' equity | 539,636 | 556,965 | ||
STANDARD BIOTOOLS INC. (LAB)
STANDARD BIOTOOLS INC. (LAB)